Systematic Review of Stem Cell Therapy for Ischemic Heart Disease in Indonesia: Where Are We Now?
Main Article Content
Abstract
Introduction: Heart failure due to IHD is one of the most common causes of morbidity in Indonesia. The promising stem cell therapy for IHD patients has been conducted in Indonesia since 12 years ago but limited results of publications are available. We conducted a systematic review to evaluate the progress of stem cell therapy for IHD patients in Indonesia. Methods: A systematic review was conducted according to the PRISMA guidelines. A comprehensive literature search was performed using the PubMed, Scopus, and Embase databases from March – April 2023. Articles are thoroughly evaluated and analyzed. Results: Four publications from Indonesia related to stem cell therapy for IHD patients are included. Clinical outcome was measured by LVEF, WMSI, and 6-MWT. Safety outcomes are also measured. Follow-up time ranged from 6 – 12 months. Significant improvement in most of the LVEF, WMSI, and 6-MWT studies. Safety outcome measures demonstrated relatively low rates of AE after stem cell transplantation and no cardiac event-related deaths were reported. Conclusion: Stem cell therapy trials for IHD in Indonesia show promising results in improving ventricular function and daily functional outcomes safely. With the fast-growing trend of stem cells and cardiovascular centers in Indonesia, we hope that more well-designed clinical trials with long-term outcome assessments can be conducted to confirm these results.
Downloads
Article Details
References
Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation. 2022 Feb 22;145(8). doi: 10.1161/CIR.0000000000001052.
Maharani A, Sujarwoto, Praveen D, Oceandy D, Tampubolon G, Patel A. Cardiovascular disease risk factor prevalence and estimated 10-year cardiovascular risk scores in Indonesia: The SMARThealth Extend study. Musinguzi G, editor. PLoS One. 2019;14(4):e0215219. doi: 10.1371/journal.pone.0215219
Li Z, Lin L, Wu H, Yan L, Wang H, Yang H, et al. Global, Regional, and National Death, and Disability-Adjusted Life-Years (DALYs) for Cardiovascular Disease in 2017 and Trends and Risk Analysis From 1990 to 2017 Using the Global Burden of Disease Study and Implications for Prevention. Front Public Heal. 2021;9:9:559751. doi: 10.3389/fpubh.2021.559751.
Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health. 2018;18(1):975. doi: 10.1186/s12889-018-5806-x.
Yu H, Lu K, Zhu J, Wang J. Stem cell therapy for ischemic heart diseases. Br Med Bull. 2017;121(1):135–54. doi: 10.1093/bmb/ldw059.
Hashimoto H, Olson EN, Bassel-Duby R. Therapeutic approaches for cardiac regeneration and repair. Nat Rev Cardiol. 2018;15(10):585–600. doi: 10.1038/s41569-018-0036-6.
Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):e4-e17. doi: 10.1161/CIR.0000000000001039.
Dababneh E, Goldstein S. Chronic Ischemic Heart Disease Selection of Treatment Modality. 2023 Jul 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 29939525. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507703/
Liu C, Han D, Liang P, Li Y, Cao F. The Current Dilemma and Breakthrough of Stem Cell Therapy in Ischemic Heart Disease. Front Cell Dev Biol. 2021;9:636136. doi: 10.3389/fcell.2021.636136.
Kementerian Kesehatan RI. Kemenkes Pastikan Layanan 4 Penyakit Katastropik Dapat Dilakukan di RSUD Kabupaten/Kota [Internet]. 2022 [cited 2023 Mar 3]. Available from: https://www.kemkes.go.id/article/view/22122400004/kemenkes-pastikan-layanan-4-penyakit-katastropik-dapat-dilakukan-di-rsud-kabupaten-kota.html
Lembaga Pengelola Dana Pendidikan. Specialist and Subspecialist Doctor Scholarships [Internet]. 2023 [cited 2023 Mar 3]. Available from: https://lpdp.kemenkeu.go.id/en/beasiswa/targeted/beasiswa-dokter-spesialis-dan-dokter-subspesialis
Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane; 2020.
The Cochrane Collaboration. Review Manager (RevMan). Version 5.4. Copenhagen: The Cochrane Collaboration; 2020.
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;i4919. doi: 10.1136/bmj.i4919.
Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014 Dec 1;14(1):45. doi: 10.1186/1471-2288-14-45.
Santoso T, Irawan C, Alwi I, Aziz A, Kosasih A, Inggriani S, Saputra A, Wintery M, Lison L. Safety and feasibility of combined granulocyte colony stimulating factor and erythropoetin based-stem cell therapy using intracoronary infusion of peripheral blood stem cells in patients with recent anterior myocardial infarction: one-year follow-up of a phase 1 study. Acta Med Indones. 2011;43(2):112-21.
Santoso T, Siu CW, Irawan C, Chan WS, Alwi I, Yiu KH, et al. Endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic heart failure: A randomized placebo-controlled trial (END-HF). J Cardiovasc Transl Res. 2014;7(6):545–52. doi: 10.1007/s12265-014-9580-6.
Yuniadi Y, Kusnadi Y, Sandhow L, Erika R, Hanafy DA, Sardjono C, et al. Progenitor hematopoietic cells implantation improves functional capacity of end stage coronary artery disease patients with advanced heart failure. Cardiol Res Pract. 2016;2016.
Soetisna TW, Sukmawan R, Setianto B, Mansyur M, Murni TW, Listiyaningsih E, et al. Combined transepicardial and transseptal implantation of autologous CD 133+ bone marrow cells during bypass grafting improves cardiac function in patients with low ejection fraction. J Card Surg [Internet]. 2020 Apr;35(4):740–6. doi: 10.1111/jocs.14454.
Abstracts of the 26th Annual Scientific Meeting of Indonesian Heart Association 2017 (26th ASMIHA), Jakarta, Indonesia, April 20–23, 2017. Eur Hear J Suppl. 2017;19(suppl_E):E1–13.
Yang JD, Cheng-Huang, Wang JC, Feng XM, Li YN, Xiao HX. The isolation and cultivation of bone marrow stem cells and evaluation of differences for neural-like cells differentiation under the induction with neurotrophic factors. Cytotechnology. 2014;66(6):1007-19. doi: 10.1007/s10616-013-9654-3.
Tian T, Chen B, Xiao Y, Yang K, Zhou X. Intramyocardial autologous bone marrow cell transplantation for ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials. Atherosclerosis [Internet]. 2014;233(2):485–92. doi:10.1016/j.atherosclerosis.2014.01.027
Xiao C, Zhou S, Liu Y, Hu H. Efficacy and safety of bone marrow cell transplantation for chronic ischemic heart disease: A meta-analysis. Med Sci Monit. 2014;20:1768–77. doi: 10.12659/MSM.892047.
Soetisna TW, Thamrin AMH, Permadijana D, Ramadhani ANE, Sugisman S, Santoso A, et al. Intramyocardial Stem Cell Transplantation during Coronary Artery Bypass Surgery Safely Improves Cardiac Function: Meta-Analysis of 20 Randomized Clinical Trials. J Clin Med [Internet]. 2023;12(13):4430. doi: 10.3390/jcm12134430.
Song J, He K, Hou J. Autologous bone marrow stem cell transplantation for patients undergoing coronary artery bypass grafting: a meta-analysis of 22 randomized controlled trials. J Cardiothorac Surg [Internet]. 2022;17(1):167. doi:10.1186/s13019-022-01838-2
Ulus AT, Mungan C, Kurtoglu M, Celikkan FT, Akyol M, Sucu M, et al. Intramyocardial Transplantation of Umbilical Cord Mesenchymal Stromal Cells in Chronic Ischemic Cardiomyopathy: A Controlled, Randomized Clinical Trial (HUC-HEART Trial). Int J Stem Cells. 2020;13(3):364–76. doi: 10.15283/ijsc20075.
Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: Safety and efficacy studies. J Thorac Cardiovasc Surg. 2007;133(3).
Brickwedel J, Gulbins H, Reichenspurner H. Long-term follow-up after autologous skeletal myoblast transplantation in ischaemic heart disease. Interact Cardiovasc Thorac Surg. 2014;18(1):61–6. doi: 10.1093/icvts/ivt434.
Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B, et al. Monitoring of Bone Marrow Cell Homing Into the Infarcted Human Myocardium. Circulation. 2005;111(17):2198–202. doi: 10.1161/01.CIR.0000163546.27639.AA.
Yiu KH, Tse HF. Specific role of impaired glucose metabolism and diabetes mellitus in endothelial progenitor cell characteristics and function. Arterioscler Thromb Vasc Biol. 2014;34(6):1136-43. doi: 10.1161/ATVBAHA.114.302192.
Poole JC, Quyyumi AA. Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34 + Bone Marrow Mononuclear Cells. Stem Cells Int. 2013;2013:1–8. doi: 10.1155/2013/658480.
Komok V V., Bunenkov NS, Beliy SA, Pizin VM, Kondratev VM, Dulaev A V., et al. Evaluation of effectiveness of combined treatment of coronary heart disease - Coronary artery bypass grafting, transplantation of autologous bone marrow mononuclear cells: A randomized, blind placebo-controlled study. Vestn Transplantologii i Iskusstv Organov. 2019;21(4):54–66. doi: 10.15825/1995-1191-2019-4-54-66
Kainuma S, Miyagawa S, Toda K, Yoshikawa Y, Hata H, Yoshioka D, et al. Long-term outcomes of autologous skeletal myoblast cell-sheet transplantation for end-stage ischemic cardiomyopathy. Mol Ther. 2021;29(4):1425–38. doi: 10.1016/j.ymthe.2021.01.004.
Steinhoff G, Nesteruk J, Wolfien M, Kundt G, Börgermann J, David R, et al. Cardiac Function Improvement and Bone Marrow Response –: Outcome Analysis of the Randomized PERFECT Phase III Clinical Trial of Intramyocardial CD133+ Application After Myocardial Infarction. EBioMedicine. 2017;22:208–24. doi: 10.1016/j.ebiom.2017.07.022.
Hendrikx M, Hensen K, Clijsters C, Jongen H, Koninckx R, Bijnens E, et al. Recovery of Regional but Not Global Contractile Function by the Direct Intramyocardial Autologous Bone Marrow Transplantation. Circulation [Internet]. 2006;114(1_supplement). doi:10.1161/CIRCULATIONAHA.105.000505
Laguna G, Di Stefa No S, Maroto L, Fulquet E, Echevarría JR, Revilla A, et al. Effect of direct intramyocardial autologous stem cell grafting in the sub-Acute phase after myocardial infarction. J Cardiovasc Surg (Torino). 2018;59(2):259–67. doi: 10.23736/S0021-9509.17.10126-6.
Nasseri BA, Ebell W, Dandel M, Kukucka M, Gebker R, Doltra A, et al. Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: The Cardio133 trial. Eur Heart J. 2014;35(19):1263–74. doi: 10.1093/eurheartj/ehu007.
Ang KL, Chin D, Leyva F, Foley P, Kubal C, Chalil S, et al. Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nat Clin Pract Cardiovasc Med. 2008;5(10):663–70. doi: 10.1038/ncpcardio1321.
Pätilä T, Lehtinen M, Vento A, Schildt J, Sinisalo J, Laine M, et al. Autologous bone marrow mononuclear cell transplantation in ischemic heart failure: A prospective, controlled, randomized, double-blind study of cell transplantation combined with coronary bypass. J Hear Lung Transplant [Internet]. 2014;33(6):567–74. doi: 10.1016/j.healun.2014.02.009.
Hou D, Youssef EA-S, Brinton TJ, Zhang P, Rogers P, Price ET, et al. Radiolabeled Cell Distribution After Intramyocardial, Intracoronary, and Interstitial Retrograde Coronary Venous Delivery. Circulation [Internet]. 2005 Aug 30;112(9_supplement). doi:10.1161/CIRCULATIONAHA.104.526749
Naseri MH, Madani H, Tafti SHA, Farahani MM, Saleh DK, Hosseinnejad H, et al. Erratum: COMPARE CPM-RMI trial: Intramyocardial transplantation of autologous bone marrow-derived CD133+ cells and MNCs during CABG in patients with recent MI: A phase II/III, multicenter, placebo-controlled, randomized, double-blind clinical trial. (Cell. Cell J. 2018;20(3):449. doi: 10.22074/cellj.2018.6018.
Trifunović Z, Obradović S, Balint B, Ilić R, Vukić Z, Šišić M, et al. Funkcionalni oporavak bolesnika sa ishemijskom kardiomiopatijom lečenih implantacijom mononuklearnih ćelija koštane srži tokom aortokoronarne bajpas hirurgije. Vojnosanit Pregl. 2015;72(3):225–32.
Thamrin AMH, Soetisna TW, Ramadhani ANE, Hendarto H. Cell sheet transplantation for ischemic heart disease: a systematic review. Indian J Thorac Cardiovasc Surg. 2023;39(6):577-587. doi: 10.1007/s12055-023-01554-z.
Sandora N, Putra MA, Busro PW, Ardiansyah, Muttaqin C, Makdinata W, et al. Preparation of Cell-Seeded Heart Patch In Vitro; Co-Culture of Adipose-Derived Mesenchymal Stem Cell and Cardiomyocytes in Amnion Bilayer Patch. Cardiovasc Eng Technol [Internet]. 2022 Apr 28;13(2):193–206. doi:10.1007/s13239-021-00565-4
He X, Wang Q, Zhao Y, Zhang H, Wang B, Pan J, et al. Effect of Intramyocardial Grafting Collagen Scaffold With Mesenchymal Stromal Cells in Patients With Chronic Ischemic Heart Disease. JAMA Netw Open [Internet]. 2020 Sep 10;3(9):e2016236. doi: 10.1001/jamanetworkopen.2020.16236.
Lalu MM, Mazzarello S, Zlepnig J, Dong YY (Ryan), Montroy J, McIntyre L, et al. Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis. Stem Cells Transl Med [Internet]. 2018;7(12):857–66. doi: 10.1002/sctm.18-0120.
Qanitha A, Qalby N, Amir M, Uiterwaal CSPM, Henriques JPS, de Mol BAJM, et al. Clinical Cardiology in South East Asia: Indonesian Lessons from the Present towards Improvement. Glob Heart. 2022;17(1). doi: 10.5334/gh.1133.
Ministry of Health Republic of Indonesia. Stem Cells Trade is Highly Restricted [Internet]. 2020 [cited 2023 Mar 15]. Available from: https://www.kemkes.go.id/article/view/20011700001/stem-cell-tak-bebas-dijualbelikan.html